Two sisters are receiving a breakthrough, FDA-approved treatment for beta thalassemia at UCSF Benioff Children's Hospital, Oakland. This is the first real therapy other than monthly transfusions for a devastating disease that destines people to shorter lives.
UCSF Benioff Children’s Hospital Oakland is the first hospital in the West to administer a newly approved gene therapy to treat beta thalassemia with gene therapy, reducing the need for lifelong blood transfusions.
As part of its miniseries on Black excellence in STEM, Carry the One Radio interviewed UCSF’s Akinyemi Oni-Orisan, PharmD, PhD. The assistant professor of clinical pharmacy shares how he’s improving cardiovascular care for everyone and how he inspires confidence in himself and his students. Find it on your favorite podcast forum.
UCSF is the first hospital in California to offer pharmacogenetic testing for smarter prescribing. Testing identifies genetic makeup and tailors medications to improve efficacy and avoid lethal drug reactions.
Cystic fibrosis is missed more often in newborn screenings for non-white than white babies, creating higher risk for irreversible lung damage and other serious outcomes in Black, Hispanic, Asian, American Indian and Alaska Native newborns.
A new variation of the CRISPR-Cas9 gene editing system makes it easier to re-engineer massive quantities of cells for therapeutic applications. The approach, developed at Gladstone Institutes and UC San Francisco (UCSF), lets scientists introduce especially long DNA sequences to precise locations in the genomes of cells at remarkably high efficiencies without the viral delivery systems that have traditionally been used to carry DNA into cells.
T cells used in immunotherapy treatments can get exhausted and shut down by fighting cancer cells and tumors. Using a CRISPR-based edit on these cells’ genomes, researchers at UCSF and Gladstone Institutes have rendered the therapeutic cells more resilient against tumors.
A world-class team of researchers co-led by UCSF’s Allan Balmain, PhD, FRS, has been selected to receive a $25 million Cancer Grand Challenges award to investigate the very early stages of cancer development.
Wei Gordon was among nine finalists in the sixth annual UCSF Grad Slam, held March 31 – after a two-year hiatus due to the pandemic – competing to inform and entertain with three-minute talks based on their own research.
Brain tumor patients survived longer when treated aggressively with surgery, radiation and chemotherapy. Now, a UCSF study underscores the critical role of genomic profiling in diagnosing and grading brain tumors.
Stephen L. Hauser, MD, Professor of Neurology and Director of the UCSF Weill Institute for Neurosciences, has been chosen by the American Brain Foundation (ABF) to receive its second annual Scientific Breakthrough Award.
Not everyone needs 8 hours of sleep, say UCSF researchers. Some lucky people are “elite sleepers,” packing sleep’s benefits into 4 to 6 hours a night. Their genes may hold clues to how efficient sleep can fend off dementia.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.